SCHEMBL5763668

SCHEMBL5763668

COc1cccc(NS(=O)(=O)Cl)c1

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.59
SMN1; SMN2 Q16637 5/20 0.59
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
TSHR P16473 2/20 0.59
HTT P42858 1/20 0.59
ALDH1A1 P00352 4/20 0.57
PKM P14618 3/20 0.55
HPGD P15428 2/20 0.55
CYP19A1 P11511 1/20 0.54
POLB P06746 2/20 0.53
TP53 P04637 3/20 0.50
GAA P10253 1/20 0.50
HSD17B10 Q99714 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL309673 0.84 LMNA (0.60) LMNASMN1; SMN2MEN1KMT2ATSHR
Hydrochloric Acid SCHEMBL20502482 0.82 LMNA (0.59) LMNASMN1; SMN2MEN1KMT2ATSHR
SCHEMBL1645211 0.82 CA1 (0.62) LMNASMN1; SMN2MEN1KMT2ATSHR
SCHEMBL11785316 0.82 LMNA (0.59) LMNASMN1; SMN2MEN1KMT2ATSHR
SCHEMBL21033859 0.82 LMNA (0.59) LMNASMN1; SMN2MEN1KMT2ATSHR
SCHEMBL14689917 0.81 PTGS1 (0.63) LMNASMN1; SMN2MEN1KMT2ATSHR
SCHEMBL30873051 0.81 LMNA (0.60) LMNASMN1; SMN2MEN1KMT2ATSHR
SCHEMBL27183321 0.81 LMNA (0.60) LMNASMN1; SMN2MEN1KMT2ATSHR
SCHEMBL17227610 0.81 LMNA (0.61) LMNASMN1; SMN2MEN1KMT2ATSHR
SCHEMBL13678087 0.79 LMNA (0.56) LMNASMN1; SMN2MEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1556371-B1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR WINSTON PHARMACEUTICALS LLC (US) 2006-04-19 EP disclosed
US-20050182101-A1 Prodrugs of proton pump inhibitors GARST MICHAEL (US) 2005-08-18 US disclosed
EP-1556371-A2 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR Winston Pharmaceuticals LLC (US) 2005-07-27 EP disclosed
US-20050143423-A1 Prodrugs of proton pump inhibitors background of the invention GARST MICHAEL (US) 2005-06-30 US disclosed
US-6897227-B2 Prodrugs of proton pump inhibitors Winston Pharmaceuticals, Inc. (US) 2005-05-24 US disclosed
US-20040102484-A1 Prodrugs of proton pump inhibitors ALEVIUM PHARMACEUTICALS, INC. 2004-05-27 US disclosed
WO-2004009583-A2 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR GARST MICHAEL E (US) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102484-A1 Prodrugs of proton pump inhibitors ABCB11, SLC10A2, SI LMNA 4395/4885SMN1; SMN2 2083/4885MEN1 1514/4885
US-20050143423-A1 Prodrugs of proton pump inhibitors background of the invention ABCB11, SLC10A2, SI LMNA 4347/4885SMN1; SMN2 2578/4885MEN1 1242/4885
US-20050182101-A1 Prodrugs of proton pump inhibitors ABCB11, SLC10A2, SI LMNA 4415/4885SMN1; SMN2 2370/4885MEN1 1915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.